Our Management Team

---

With over 30 years of consulting and communications experience, Terry Lierman has served clients within both private and public sectors across core industries including health, energy and education. Terry Lierman has provided a variety of organizations with media relations advisement, communications management, business sustainability and program administration. Terry is currently the founding partner of Summit Global Ventures LLC where he consults and invests in promising health, medical device and energy related companies. He has also played integral roles in the business development and patient education of health information technology for organizations like Eneura Corporation and CSGI. Terry worked as Chief of Staff to both the Democratic Whip and the current Majority

Leader of the US House of Representatives. During that time, Terry oversaw and directed various duties and responsibilities within the office, including management of staff, policy and floor initiatives and directives. Prior to going to the Hill, Terry displayed his health development and program administration skills in executive positions at Health Ventures, TheraCom and Employee Health Programs as he consulted on business plans, feasibility and public relations. Early in his career, Terry founded and directed a consulting firm, Capitol Associates Inc., where he provided government and public relations services for various organizations within a wide scope of fields. It was here that Terry honed expertise on health research, budgetary processes, services administration and program development. Terry Lierman has served on multiple boards and community service organizations including such as, New York Life Insurance, The MAINSTAY Mutual Funds’ Board, Founded the National Coalition for Center Research, and Children’s Research Institute at Children’s Hospital National Medical Center. Terry has an undergraduate degree from Winona State University and a graduate degree from the University of Wisconsin, Madison.

           Dipak has over 20 years of experience in operation, management and general administration. Currently, Dipak serves as the CEO of Stellar IT Solutions, an Information Technology consulting and product development company.

          Dipak started his career as an entrepreneur when he created a portfolio of investments in real estate and various restaurant business. Started in 2003, this investment portfolio grew to over $30 mil in market value. For over 10 years, Dipak remained closely involved in the day to day operations of these portfolio of businesses.

Subsequently, Dipak served as a Program Director at FINRA (Financial Industry Regulatory Authority). As the Program Director for Insiders Trading and Fraud Detection, Dipak was responsible for research and development of Financial Models to detect Insider Trading and Fraud in the all the three major US stock markets - Nasdaq, NYSE and Amex. Under Dipak’s leadership, the Surveillance and Detection team

researched and developed many complex financial models using various financial theories and statistical methodologies. A graduate of the University of Maryland - College Park, Dipak holds a Business

Administration Degree with a major in Finance and Investment Management. He also holds a Master’s Degree in computer science from DDIT Engineering institute in India.

          Joseph Fortunak is a Professor of Chemistry and Pharmaceutical Sciences at Howard University in Washington DC. Dr. Fortunak holds several honorary appointments at institutions in the US and overseas. He teaches a comprehensive program of Good Manufacturing Practice, Regulatory Science, and Drug Manufacturing in Africa and elsewhere. 

          Dr. Fortunak previously spent 21 years in the originator pharmaceutical industry, where he discovered, managed, and implemented the chemistry for manufacturing 15 new drugs and 25+ generic products with total sales of over $200 billion. He has managed as many as 500 people and budgets of $150 million/year while manufacturing APIs for R&D and commercial use.

          At SmithKline Beecham Corp. (now GlaxoSmithKline), Dr. Fortunak led the chemistry for the API manufacturing processes for eprosartan (cardiovascular/renal), halofantrine (malaria), ropinirole (Parkinsons Disesase/restless leg syndrome), and topotecan (cancer). At Dupont Merck, Dr. Fortunak led the API chemistry for

efavirenz (HIV), losoxantrone (cancer), and validation for losartan (cardiovascular). He also managed the chemistry and major revisions of DMFs (new routes of synthesis) for the APIs naltrexone, and naloxone. At Abbott Labs he oversaw the approval and launch of APIs

including heat-stable kaletra (HIV), fenofibric acid/trilipix, and validation of adalimumab (multiple inflammatory diseases). Also, while at Abbott Dr. Fortunak led R&D and Commercial groups that handled regulatory filings and manufactured 30+ APIs for commercial sale including risedronate, sterile valproic acid, propofol, sevoflurane,

midazolam, cis-atracurium, kanamycin, and emtricitabine. This included the filing and maintenance of CMC packages for new drugs and Drug Master Files (DMFs) including complex generics such as the peptide cancer drug leuprolide. He has worked on several 505(b)(2) filings including fenofibrate, fenofibric acid, and naltrexone.

          Dr. Fortunak’s research includes Green Chemistry; novel, leap-frogging technologies; and pharmacokinetic enhancers to reduce the cost/toxicity of medicines and promote sustainable, global access.  Dr. Fortunak has worked with pharmaceutical companies, government agencies, and non-Governmental Organizations in the US, India, China, and Africa including the US FDA, USAID, WHO, UNAIDS, UNITAID, UNIDO, USP, and the Global Fund for AIDS, TB, and Malaria.

          Dr. Fortunak’s work in API production is represented in over 22 million people taking HIV medicines daily in low- and middle-income countries (LMICs). These efforts reduced the cost of treating people with Hepatitis C and AIDS in LMICs by $1.85 billion in 2013-2017 alone. He has received numerous awards including the American Chemical Society “Heroes of Chemistry”, and a US FDA Honor Award for Excellence and Innovation in Africa. Dr. Fortunak has over 100 publications and 35+ patents and patent applications.

          Kevin Zhang is the President of International Operations and an Investment Partner at Century Galaxy Technology Group. Century Galaxy Technology Group is a healthcare investment holding company, focusing on investing in healthcare technologies and

services globally. Century Galaxy has over 90 investments in multiple health care sectors with totally market value $9 billion USD and close to $3 billion USD in revenue (2019). Under Mr. Zhang’s leadership in the past 4 years, Century Galaxy has grown into an international investment management platform, with three international regional

affiliates in USA, Germany and Singapore, over 10 direct investments under management.

          Prior to Century Galaxy, Kevin spent many years in investment management, startups, and business management in USA, Canada, Western Europe, and China. Kevin started his career 20 years ago in Shenzhen, China as a medical device distributor. He then

moved to Toronto, Canada in 2005 and successfully launched and managed his 1st medical device startup in Oncology space. From 2009 to 2016, Kevin led and managed multiple medical products global commercialization process in IVD and Cardiovascular areas for Abbott Laboratories in Europe and North America.

          Kevin has a BS degree in Electric Engineering from Hebei University of Technology in Tianjin, China and an MBA from Kelley School of Business, Indiana University.